Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans.
Ipratropium bromide (ipratropium) and tiotropium bromide (tiotropium), anticholinergic agents with bronchodilating properties, are used to treat patients with chronic obstructive pulmonary disease. Because they are actively secreted into urine, the interaction of these agents with organic cation transporters (OCTs/Octs) was examined in rat kidney slices and in cultured cells expressing rat Oct (rOct) or human OCT (hOCT). Uptake of radiolabeled ipratropium in rat kidney slices was significantly inhibited by OCT/Oct substrates including cimetidine, imipramine, and quinidine, but not by organic anion transporter substrates (e.g., p-aminohippuric acid and estrone-3-sulfate). [(3)H]Tiotropium uptake showed similar characteristics. Reverse transcription-polymerase chain reaction showed that, in rat kidney, mRNA expression of rOct2 was the highest, followed by rOct1, but little rOct3 was detected. In vitro, rOct1 and rOct2 transported both anticholinergics, but rOct3 accepted only ipratropium. Ipratropium uptake by rat kidney slices consisted of two components with K(m) values of 0.114 ± 0.06 and 24.5 ± 2.21 μM. The K(m) value of rOct2-mediated ipratropium uptake (0.143 ± 0.03 μM) was consistent with that of the high-affinity component. The OCT/Oct inhibitor corticosterone, at a concentration of 1 μM (IC(50), 1.11 ± 0.20 μM for rOct2-mediated ipratropium transport), inhibited ipratropium by 18.4%, suggesting that rOct2 is involved in renal secretion of ipratropium. In a similar manner, ipratropium and tiotropium were taken up by cultured cells expressing hOCT1 and hOCT2 but not hOCT3. We conclude that OCT2/Oct2 plays a role in renal secretion of both anticholinergics in these species. Coadministration of these anticholinergics with cationic drugs recognized by OCT2/Oct2 may decrease renal clearance, resulting in increased systemic exposure.
Nakanishi
Takeo
T
Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan.
Haruta
Tsunemitsu
T
Shirasaka
Yoshiyuki
Y
Tamai
Ikumi
I
D000818:Animals; D018680:Cholinergic Antagonists / Q000378:metabolism* / Q000494:pharmacology; D003345:Corticosterone / Q000494:pharmacology; D057809:HEK293 Cells; D006801:Humans; D066298:In Vitro Techniques; D009241:Ipratropium / Q000032:analysis* / Q000378:metabolism* / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism*; D008297:Male; D027701:Organic Cation Transport Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012602:Scopolamine Derivatives / Q000378:metabolism* / Q000494:pharmacology; D000069447:Tiotropium Bromide
D018680:Cholinergic Antagonists; D027701:Organic Cation Transport Proteins; D012333:RNA, Messenger; D012602:Scopolamine Derivatives; D009241:Ipratropium; D003345:Corticosterone; D000069447:Tiotropium Bromide